Macular Neovascularization Secondary to Age-Related Macular Degeneration
Ophthalmology·MeSH: Macular Degeneration
Prevalence
2000.0 / 100K
Incidence
200.0 / 100K/yr
4 drugs in development·2 companies·1 clinical trial
Drug Pipeline by Phase
Compare drugs
Frequently asked questions
How many drugs are in development for Macular Neovascularization Secondary to Age-Related Macular Degeneration?
BioSniper tracks 4 drugs in development for Macular Neovascularization Secondary to Age-Related Macular Degeneration across 2 companies.
How many clinical trials target Macular Neovascularization Secondary to Age-Related Macular Degeneration?
There are 1 clinical trial targeting Macular Neovascularization Secondary to Age-Related Macular Degeneration tracked by BioSniper.
What is the prevalence of Macular Neovascularization Secondary to Age-Related Macular Degeneration?
The estimated prevalence of Macular Neovascularization Secondary to Age-Related Macular Degeneration is approximately 2000.0 per 100,000 population.
Deep-dive into Macular Neovascularization Secondary to Age-Related Macular Degeneration
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis